GENE EDITING 101
All Companies
🇺🇸

NewLimit

Private

Epigenetic reprogramming for human rejuvenation

Co-founded by Coinbase's Brian Armstrong, NewLimit is developing epigenetic reprogramming therapies to treat age-related diseases. The company focuses on understanding and reversing epigenetic changes that drive aging.

Founded2021
HQSouth San Francisco, CA
CEOBlake Byers
StatusPrivate
Total Funding$130M

Pipeline

Drug / ProgramIndicationPhaseTechnology
T-cell reprogrammingImmune agingPreclinicalEpigenetic Reprogramming

Key People

Blake ByersCEO
Brian ArmstrongCo-founder

Related Articles

Every Longevity Biotech Company You Should Know in 2026
Longevity Science
Market Analysis

Every Longevity Biotech Company You Should Know in 2026

From billion-dollar reprogramming ventures to canine longevity drugs, here are the biotech companies leading the charge against aging in 2026.

Mar 25, 20268 min read